INTERVIEW: Accrol Group Holdings Plc- Zeus Expect Double Digit Revenue Growth

Accrol Group Holdings plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Accrol Group Holdings PLC (LON:ACRL) are the topic of conversation today when DirectorsTalk caught up with Mike Allen, Head of Research at Zeus Capital. Mike shares his thoughts on today’s trading statement from the company, explains his forecast assumptions and shares his view on the current stock valuation.

Accrol has this morning released an encouraging trading update, essentially confirming that the company is continuing to trade in line with expectations and the strategy is progressing well. We are maintaining our forecast assumptions for now, despite a “less favorable macro-economic environment”. While the shares have performed well of late, we believe the valuation remains attractive given its growth potential and unique market positioning and believe the risk/reward profile remains positive from here.

Trading update: The company have released a confident trading update, confirming that it has performed in line with market expectations for the 12-month period ended 30 April 2017. This is despite the macro economic environment being “less favorable.”, That said, we remain of the view that during a period of higher inflation, more consumers will move into the discount sector and private label products where Accrol is well positioned. We would also anticipate that hedging arrangements both in terms of US$ and agreed paper prices are in place for the new financial year to April 2018. Final results will be announced on 10 July.

Consolidating its market position: Accrol Group Holdings Plc has consolidated its position as market leader in the discount sector and following the investment and smooth integration of its 168,000 sq.ft facility in Leyland, is running at production capacity of 143,000 tonnes per annum (118,000 at IPO). The company has announced, this morning, a 10-year lease agreement on a 368,000 sq.ft warehouse in West Lancashire to allow for further expansion, and this is testament to its confidence in executing its growth strategy, in our view. This facility will store finished goods and provide central distribution to all UK customers, enabling it to simplify and consolidate its existing warehouse facilities.

Forecast assumptions: We are maintaining our forecast assumptions at this juncture. We are forecasting a 4-year revenue CAGR through to 2019E of 10%, with cautious gross and EBITDA margins given the current environment, which will deliver a CAGR on the same basis in adjusted EPS of more than 20%, which is also backed by a rising ROCE (post tax) profile that should move in excess of 20% by 2019 vs. 15.4% expected in 2017E. We are also anticipating a 10% growth rate in DPS every year.

Valuation: The shares are currently trading on a 2018E P/E of 11.9x and an EV/EBITDA of 8.6x, which we believe remains attractive for a business expected to deliver EPS growth >15% per annum through to 2019E with a rising post tax ROCE >15% and a FCF yield of 8-10%. Given the significant investment in growth and capacity, we remain very comfortable with our original thesis that this should be a £30m+ EBITDA business based on 200,000 tonnage capacity. Overall, we remain comfortable with the investment case, and believe the risk/reward profile is positive from here.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Accrol Group Holdings plc (LON:ACRL) has announced the publication of a shareholder circular detailing terms of the Scheme. Learn more here.
Discover the latest results and overview of Accrol Group Holdings, the UK's top independent tissue converter, led by CEO Gareth Jenkins and CFO Chris Welsh.
In this interview, Gervais Williams, co-fund manager of Miton UK MicroCap Trust, discusses navigating the economic landscape and standout companies in 2024. Find out more here. #investment #microcap
Accrol Group Holdings plc has reported strong H1 FY24 results, with impressive growth in adjusted EBITDA and adjusted PBT. The company remains on track to meet expectations and has seen gains in market share. Furthermore, the private label segment of the UK tissue market continues to increase, and the sales of biodegradable wet wipes have been exceptionally strong. Accrol's outlook remains positive with expected further volume growth.
Accrol Group Holdings plc has reported strong performance in H1 FY24, with branded volumes rising by 45% and margins returning to pre-pandemic levels. The group is on track to deliver FY24 results in line with expectations and expects to outperform previous expectations for FY25.

Search

Search